Loading
A phase 3 trial of pembrolizumab, pemetrexed and carboplatin in lung cancer, run by Institut Bergonié, now recruiting.
Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma is a phase 3, randomised interventional study registered as NCT04339218 by Institut Bergonié, with a registry enrolment figure of 214 participants, started 2020-08-28 and due to reach its primary completion in 2026-08-27. Interventions recorded: Cryoablation; Pembrolizumab; Pemetrexed; Carboplatin. Conditions listed: Lung Adenocarcinoma; Cryotherapy Effect. Primary outcome: 1-year overall survival rate. Lung eligibility wording from the registry: "Histologically or cytologically confirmed non-small lung adenocarcinoma". Sites: France. No results are recorded here; the registry entry is the source.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Lung cancer (all types), Pembrolizumab and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin and the tag lung-deep-dive.